- Therma Bright (THRM) has signed a definitive partnership agreement with Afero Inc. to integrate Afero’s smart platform into the AcuVid rapid test cartridge
- The smart-enabled AcuVid will initially be used to screen for COVID-19 in airports, hospitals, medical facilities, schools, businesses, stadiums, and event venues
- Therma Bright has submitted the product to the FDA-EUA for point-of-care approval
- Therma Bright is a medical technology company
- Therma Bright Inc. (THRM) is up 3.41 per cent, trading at $0.455 per share
Therma Bright (THRM) has signed a definitive partnership agreement with Afero Inc., an Internet of Things platform developer.
Under the agreement, Therma Bright will embed Afero’s Intelligent Edge smart platform into its AcuVid™ saliva test cartridge.
AcuVid is a rapid antigen saliva test used to detect COVID-19 and its variants. With Afero’s platform, the smart-enabled test will allow users to display a negative test result on their health passports, allowing access to public areas.
“The AcuVid™ COVID-19 Rapid Antigen Saliva Test, powered by Afero, has always had the main goal of helping communities safely and securely stay open or re-open during this COVID-19 pandemic,” said Afero CEO Joe Britt.
Rob Fia, CEO of Therma Bright, also commented on the partnership and the new product offering.
“Initially we see our smart-enabled testing solution ideal for facilities who have their own healthcare practitioners onsite,” he remarked.
The company envisions that AcuVid will initially be used in airports, hospitals, medical facilities, schools, businesses, stadiums, and event venues.
“These are the places where the public come to connect for work, play or education, and are also places where people are most susceptible to catching and spreading this horrible virus and its growing list of variants,” said Mr. Fia.
Therma Bright has submitted the product to the FDA-EUA for point-of-care approval. Once that is granted, the smart-enabled test will be submitted for at-home use approval.
“That’s when the true power of the Afero solution will come into play by integrating with a person’s health passport for test verification,” said Mr. Britt.
Therma Bright is a medical technology company. Other than its AcuVid test, the company is focused on using its thermal therapy technology to develop dermatological products for the medical device field.
Therma Bright Inc. (THRM) is up 3.41 per cent, trading at $0.455 per share as of 9:33 am ET.